Key Points
- Harlan Robins sold 470,266 shares on March 11 at an average price of $13.17 for proceeds of about $6.19M, cutting his direct stake by 23.6% to 1,522,058 shares (worth ≈$20.05M).
- Multiple insiders sold roughly 1.25M shares for about $16.6M between March 11–13, a coordinated round of insider selling that investors may view negatively as added supply or liquidity-taking.
- Adaptive beat the Feb. 5 quarterly EPS estimate (‑$0.09 vs ‑$0.19) with revenue up ~51% YoY to $71.7M, but remains unprofitable (negative net margin and ROE); consensus is a Moderate Buy with a $18.25 price target.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $245,910.24. Following the completion of the sale, the chief financial officer directly owned 259,840 shares of the company's stock, valued at approximately $3,422,092.80. This trade represents a 6.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Kyle Piskel also recently made the following trade(s):
- On Wednesday, February 4th, Kyle Piskel sold 2,145 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.46, for a total transaction of $39,596.70.
- On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $77,220.00.
Adaptive Biotechnologies Trading Up 5.8%
Shares of ADPT stock opened at $13.17 on Friday. The firm's 50 day moving average is $16.55 and its 200 day moving average is $15.85. The stock has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12 month low of $6.68 and a 12 month high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies's revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) EPS. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Institutional Investors Weigh In On Adaptive Biotechnologies
Institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd bought a new stake in Adaptive Biotechnologies during the fourth quarter valued at $28,000. Sound Income Strategies LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter worth about $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $51,000. Hedge funds and other institutional investors own 99.17% of the company's stock.
Key Stories Impacting Adaptive Biotechnologies
Here are the key news stories impacting Adaptive Biotechnologies this week:
- Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
- Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
- Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.
Analysts Set New Price Targets
A number of research firms recently issued reports on ADPT. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an "equal weight" rating and a $21.00 price objective on the stock. BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, February 6th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research report on Friday, February 6th. Guggenheim increased their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, TD Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $18.25.
View Our Latest Report on ADPT
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
